Too Few Diabetes Patients Receiving Statins
Last Updated: September 13, 2016.
http://www.doctorslounge.com/index.php/news/pb/66457
Nearly all middle-aged patients with diabetes should be taking statins, but cardiologists fail to prescribe these medications for two out of every five such patients in their care, according to a study published in the Sept. 20 issue of the Journal of the American College of Cardiology.
TUESDAY, Sept. 13, 2016 (HealthDay News) -- Nearly all middle-aged patients with diabetes should be taking statins, but cardiologists fail to prescribe these medications for two out of every five such patients in their care, according to a study published in the Sept. 20 issue of the Journal of the American College of Cardiology.
Researchers analyzed the records of 215,193 patients (age 40 to 75 years) with diabetes but no overt cardiovascular disease who visited a cardiologist between May 2008 and October 2013. The data on the patients came from 204 cardiology practices.
The researchers found that only 61.6 percent of patients were prescribed a statin. Those prescribed statins were more likely to have cardiovascular risk factors. They also were more likely to receive non-statin cholesterol-lowering therapy (28 percent, versus 13 percent for patients not receiving a statin) and had lower mean low-density lipoprotein cholesterol (90 versus 103 mg/dL). The team noted a 57 percent variation in statin prescribing practices, even after accounting for individual patient factors such as age, gender, race, hypertension, dyslipidemia, tobacco use, and insurance coverage.
"The new cholesterol guideline recommends statin therapy in diabetic patients 40 to 75 years of age with low-density lipoprotein cholesterol 70 to 189 mg/dL without atherosclerotic cardiovascular disease," the authors write. "The current gap in care identified in this study supports national efforts to improve the use of statins in patients with diabetes."
Full Text (subscription or payment may be required)
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment